Dr. John Crawford, MD, MS
Claim this profileRady Children's Hospital
Studies Brain Tumor
Studies Brain Cancer
8 reported clinical trials
17 drugs studied
Area of expertise
1Brain Tumor
H3.3K27M positive
H3F3A
IDH positive
2Brain Cancer
IDH positive
Affiliated Hospitals
Clinical Trials John Crawford, MD, MS is currently running
Individualized Treatment
for Medulloblastoma
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.
Recruiting1 award N/A
Trametinib + Everolimus
for Recurrent Brain Cancer
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone.
Recruiting1 award Phase 135 criteria
More about John Crawford, MD, MS
Clinical Trial Related12 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments John Crawford, MD, MS has experience with
- Nivolumab
- K27M Peptide
- Cisplatin
- Cyclophosphamide
- Vismodegib
- Vincristine
Breakdown of trials John Crawford, MD, MS has run
Brain Tumor
Brain Cancer
Solid Tumors
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Crawford, MD, MS specialize in?
John Crawford, MD, MS focuses on Brain Tumor and Brain Cancer. In particular, much of their work with Brain Tumor has involved H3.3K27M positive patients, or patients who are H3F3A.
Is John Crawford, MD, MS currently recruiting for clinical trials?
Yes, John Crawford, MD, MS is currently recruiting for 4 clinical trials in San Diego California. If you're interested in participating, you should apply.
Are there any treatments that John Crawford, MD, MS has studied deeply?
Yes, John Crawford, MD, MS has studied treatments such as Nivolumab, K27M peptide, Cisplatin.
What is the best way to schedule an appointment with John Crawford, MD, MS?
Apply for one of the trials that John Crawford, MD, MS is conducting.
What is the office address of John Crawford, MD, MS?
The office of John Crawford, MD, MS is located at: Rady Children's Hospital, San Diego, California 92123 United States. This is the address for their practice at the Rady Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.